Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT06548607 is registered in ClinicalTrials.gov with Nanjing Bioheng Biotech Co., Ltd. as lead sponsor.

NCT NCT06548607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06548607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Lead sponsor
Nanjing Bioheng Biotech Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 14, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, autoimmune diseases, idiopathic inflammatory myopathies, sjogren's syndrome, sle (systemic lupus), systemic sclerosis